XML 29 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6
Basis of Presentation and Summary of Significant Accounting Policies (Details) (USD $)
3 Months Ended 9 Months Ended 3 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2012
Sep. 30, 2012
Jun. 30, 2012
Auction rate securities
Sep. 30, 2012
Recurring basis
Total
Dec. 31, 2011
Recurring basis
Total
Sep. 30, 2012
Recurring basis
Total
Money market funds
Dec. 31, 2011
Recurring basis
Total
Money market funds
Sep. 30, 2012
Recurring basis
Total
Corporate debt securities
Dec. 31, 2011
Recurring basis
Total
Corporate debt securities
Sep. 30, 2012
Recurring basis
Total
U.S. treasury and government agency securities
Dec. 31, 2011
Recurring basis
Total
U.S. treasury and government agency securities
Sep. 30, 2012
Recurring basis
Total
Commercial paper
Dec. 31, 2011
Recurring basis
Total
Commercial paper
Dec. 31, 2011
Recurring basis
Total
Auction rate securities
Sep. 30, 2012
Recurring basis
Quoted Prices in Active Markets for Identical Assets (Level 1)
Dec. 31, 2011
Recurring basis
Quoted Prices in Active Markets for Identical Assets (Level 1)
Sep. 30, 2012
Recurring basis
Quoted Prices in Active Markets for Identical Assets (Level 1)
Money market funds
Dec. 31, 2011
Recurring basis
Quoted Prices in Active Markets for Identical Assets (Level 1)
Money market funds
Sep. 30, 2012
Recurring basis
Significant Other Observable Inputs (Level 2)
Dec. 31, 2011
Recurring basis
Significant Other Observable Inputs (Level 2)
Sep. 30, 2012
Recurring basis
Significant Other Observable Inputs (Level 2)
Corporate debt securities
Dec. 31, 2011
Recurring basis
Significant Other Observable Inputs (Level 2)
Corporate debt securities
Sep. 30, 2012
Recurring basis
Significant Other Observable Inputs (Level 2)
U.S. treasury and government agency securities
Dec. 31, 2011
Recurring basis
Significant Other Observable Inputs (Level 2)
U.S. treasury and government agency securities
Sep. 30, 2012
Recurring basis
Significant Other Observable Inputs (Level 2)
Commercial paper
Dec. 31, 2011
Recurring basis
Significant Other Observable Inputs (Level 2)
Commercial paper
Dec. 31, 2011
Recurring basis
Significant Unobservable Inputs (Level 3)
Dec. 31, 2011
Recurring basis
Significant Unobservable Inputs (Level 3)
Auction rate securities
Sep. 30, 2012
Nonrecurring basis
Sep. 30, 2012
Nonrecurring basis
Use of Estimates and Assumptions                                                            
Reduction of clinical trial accruals $ 1,200,000                                                          
Reduction in estimated clinical trial costs, impact per basic and diluted share (in dollars per share) $ 0.06 $ 0.06                                                        
Fair value of assets measured on a recurring and nonrecurring basis                                                            
Fair value of assets       209,443,000 222,225,000 41,500,000 55,995,000 104,787,000 94,626,000 56,662,000 48,086,000 6,494,000 5,991,000 17,527,000 41,500,000 55,995,000 41,500,000 55,995,000 167,943,000 148,703,000 104,787,000 94,626,000 56,662,000 48,086,000 6,494,000 5,991,000 17,527,000 17,527,000    
Aggregate par value of auction rate securities sold during the period     19,800,000                                                      
Proceeds from the sale of ARS holdings     18,300,000                                                      
Fair market value of assets held for sale 2,300,000 2,300,000                                                     2,300,000 2,300,000
Accelerated depreciation of assets held for sale $ 1,100,000 $ 1,400,000                                                     $ 1,100,000 $ 1,400,000